BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer

Pancreas. 2020 Nov/Dec;49(10):e101-e103. doi: 10.1097/MPA.0000000000001672.

Authors

Tomohiro Kondo¹, Masashi Kanai, Junichi Matsubara, Pham Nguyen Quy, Keita Fukuyama, Yoshihiro Yamamoto, Takahiro Yamada, Masakazu Nishigaki, Sachiko Minamiguchi, Masayuki Takeda, Kazuto Nishio, Shigemi Matsumoto, Manabu Muto

Affiliation

¹ Department of Therapeutic Oncology Graduate School of Medicine Kyoto University Kyoto, Japan [email protected] Clinical Genetics Unit Kyoto University Hospital Kyoto, Japan Department of Diagnostic Pathology Kyoto University Hospital Kyoto, Japan Department of Medical Oncology Kindai University Faculty of Medicine Osaka, Japan Department of Genome Biology Kindai University Faculty of Medicine Osaka, Japan Department of Therapeutic Oncology Graduate School of Medicine Kyoto University Kyoto, Japan.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / genetics*
Adenocarcinoma / pathology
Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
BRCA2 Protein / genetics*
Biomarkers, Tumor / genetics*
DNA Mutational Analysis*
Drug Resistance, Neoplasm / genetics
Female
Fluorouracil / therapeutic use
Genetic Predisposition to Disease
Humans
Irinotecan / therapeutic use
Leucovorin / therapeutic use
Liquid Biopsy
Mutation*
Oxaliplatin / therapeutic use
Pancreatic Neoplasms / drug therapy
Pancreatic Neoplasms / genetics*
Pancreatic Neoplasms / pathology
Phenotype
Predictive Value of Tests
Treatment Outcome

Substances

BRCA2 Protein
BRCA2 protein, human
Biomarkers, Tumor
folfirinox
Oxaliplatin
Irinotecan
Leucovorin
Fluorouracil